Unknown PHASE1 INTERVENTIONAL 1-arm NCT04958187

Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects

An Open Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of ANG-3777 Injected Intravenously in Stable Adult Maintenance Hemodialysis Subjects

Sponsor: Angion Biomedica Corp

Conditions Hemodialysis

Interventions ANG-3777

Updated 4 times since 2021 Last updated: Jul 9, 2021 Started: Jul 31, 2021 Primary completion: Oct 31, 2021 Completion: Oct 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hemodialysis and is currently ongoing. Angion Biomedica Corp leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jul 2023 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Sep 2021 — Jul 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Angion Biomedica Corp
Nucleus Network Ltd

Data source: Angion Biomedica Corp

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Minneapolis, United States